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Abstract
Background: The efficacy of selective cox-2 inhibitors in postoperative pain reduction were usually compared with
conventional non-selective conventional NSAIDs or other types of medicine. Previous studies also used selective
cox-2 inhibitors as single postoperative dose, in continued mode, or in combination with other modalities. The
purpose of this study was to compare analgesic efficacy of single preoperative administration of etoricoxib versus
celecoxib for post-operative pain relief after arthroscopic anterior cruciate ligament reconstruction.
Methods: One hundred and two patients diagnosed as anterior cruciate ligament injury were randomized into
3 groups using opaque envelope. Both patients and surgeon were blinded to the allocation. All of the patients
were operated by one orthopaedic surgeon under regional anesthesia. Each group was given either etoricoxib
120 mg., celecoxib 400 mg., or placebo 1 hour prior to operative incision. Post-operative pain intensity, time to first
dose of analgesic requirement and numbers of analgesic used for pain control and adverse events were recorded
periodically to 48 hours after surgery. We analyzed the data according to intention to treat principle.
Results: Among 102 patients, 35 were in etoricoxib, 35 in celecoxib and 32 in placebo group. The mean age of
the patients was 30 years and most of the injury came from sports injury. There were no significant differences in
all demographic characteristics among groups. The etoricoxib group had significantly less pain intensity than the
other two groups at recovery room and up to 8 hours period but no significance difference in all other evaluation
point, while celecoxib showed no significantly difference from placebo at any time points. The time to first dose of
analgesic medication, amount of analgesic used, patient’s satisfaction with pain control and incidence of adverse
events were also no significantly difference among three groups.
Conclusions: Etoricoxib is more effective than celecoxib and placebo for using as preemptive analgesia for acute
postoperative pain control in patients underwent arthroscopic anterior cruciate ligament reconstruction.
Trial registration number: NCT01017380
Background
Multimodal or balanced analgesia, using a combination
of analgesics throughout the perioperative period to con-
trol postoperative pain, has been increasingly popular
and well accepted [1,2]. Nonsteroidal anti-inflammatory
drugs (NSAIDs) have a significant role in postoperative
pain control as they reduce the use of opioids [3-5]
which were associated with a variety of postoperative side
effects, such as ventilatory depression, drowsiness and
sedation, nausea and vomiting, pruritus, urinary reten-
tion, ileus and constipation [6,7]. The nonselective
NSAIDs inhibit both forms of the cycloxygenase (COX)
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enzymes. The efficacy of NSAIDs for the treatment of
pain is due to the inhibition of the COX-2 enzyme,
whereas the inhibition of the COX-1 enzyme may lead to
disturbance of normal platelet function and gastrointest-
inal toxicity [8,9]. Selective COX-2 inhibitors offer signif-
icantly less gastrointestinal toxicity and no effects on
platelet aggregation [10], therefore are more suitable for
perioperative use. A number of studies have shown that
these selective COX-2 inhibitors are effective in reducing
pain in postoperative period [3-5,7,11-17] and more
effective if given both before and after surgery [5,18] .
From meta-analysis, a single oral dose of either etoricoxib
or celecoxib is an effective means of postoperative pain
relief [19,20]. However, we could not find any study of
efficacy of single oral dose of these medicines given pre-
operatively. Furthermore, the comparisons where usually
made between selective cox-2 inhibitors and conven-
tional NSAIDs or other medicines. There has been no
head-to-head comparison study between these two novel
selective COX-2 inhibitors in terms of postoperative pain
reduction. The purposes of this study comparing the effi-
cacy of preoperative administrations of etoricoxib versus
celecoxib and placebo for post-operative pain relief after
arthroscopic anterior cruciate ligament reconstruction
are to evaluate the efficacy of single preoperative dose of
selective cox-2 inhibitors and whether there is any super-
iority among selective cox-2 inhibitors currently available
in the market.
Methods
This study was approved by the Ethic Committee of
our Faculty. The patients diagnosed as anterior cruciate
ligament injury aged between 15 to 50 years old who
scheduled for arthroscopic anterior cruciate ligament
reconstruction (ACLR) in Songklanagarind hospital during
January 2008-January 2009 was included in the study. We
excluded the patients who had known allergy, sensitivity
or contra-indications to opioids or NSAIDs, having a his-
tory of dyspepsia, peptic ulcer or abnormal bleeding, cor-
onary and peripheral arterial diseases as well as allergy to
sulfonamide group. The patients who had used NSAIDs,
opioids, salicylate within 7 days of the operation were also
excluded. The patients were randomized into 3 groups;
etoricoxib,celecoxib and placebo using random table
containing in the opaque envelope. In etoricoxib group,
120 mg of etoricoxib was orally given. In celecoxib group,
400 mg was given 1 hour before the incision as same as in
the controlled group. Both the surgeon and the assessors
were blinded to the result of allocation. As a currently
common treatment protocol in our country where the
hospital cost is inexpensive and for the purpose of direct
pain observation, all patients were admitted a night before
surgery and discharged at 48 hours post-operatively. The
operations were performed under spinal anesthesia using
0.5% hyperbaric bupivacaine without additional intrathecal
opioid. The arthroscopic anterior cruciate ligament recon-
structions were performed by the principle investigator
using autograft bone-patellar tendon-bone. The operative
time were recorded. At the end of the operation, all the
remaining intra-articular fluid was squeezed out, a vacuum
drain was placed intra-articularly and the operative wound
was closed before the tourniquet was released. The total
drain amount was recorded at 48 hours before removal.
All subjects were treated in routine fashion in the
recovery room. They were kept until they recovered
from the spinal anesthesia and satisfied with recovery
room scoring system. The operated knees were locked
at in full extension with hinge knee brace for 48 hours
and allowed for 0-90 degrees motion at 48 hours when
the drain had been removed and wound had been dres-
sing changed. During the post-operative period, the
patients were asked to quantify their pain using a Verbal
Analog Pain Scale (VbAPS) of 0-100 mm. where 0
represents no pain and 100 mm for unbearable pain.
The first pain evaluation was made just before they left
the recovery room and then repeated at 4, 8,12, 16, 20,
24, 30, 36, 42 and 48 hours postoperatively. The post-
operative pain medications allowed were oral paraceta-
mol 1000 mg taken as needed every 6 hours and/or
intravenous fentanyl 1 microgram per kilogram taken
every 3 hours as requested by patients. The time to first
use of each analgesic medication was recorded. The
total amount of both medications was recorded at 48
hours. The patients were also asked to grade their satis-
faction with pain control at 48 hours using a Verbal
Analog Pain Scale (VbAPS) of 0-100 mm, where 0
represent dissatisfy and 100 mm for most satisfy. The
primary outcome of this study was a comparison of the
postoperative pain levels in the three groups, while the
secondary outcomes were the time to first analgesic
analgesics, total amount of analgesics used, the amount
of drain output (as represent blood loss) and patients’
satisfaction with their pain control. The vital signs were
recorded regularly. All adverse drug reactions and side
effects were also recorded.
Statistical analysis
The sample size required for this study was 32 patients in
each arm. The calculation relied on the primary outcome;
post-operative pain intensity, which from previous study
found the standard deviations of celecoxib and etoricoxib
to be 0.2 and 0.3, respectively. The sample size was based
on a 2-sided test with 80% power and a significant level
of 0.05. All statistical calculation was performed using
STATA version 9.0.We analyzed the data based on inten-
tion-to-treat principle. Either chi-square or Fisher’s exact
test was used to analyze categorical outcomes. Differ-
ences among 3 groups of continuous variables were
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analyzed by analysis of variance (ANOVA). Post-hoc ana-
lysis was performed with Bonferroni test.
Results
Among 102 patients, 35 were in etoricoxib, 35 in cele-
coxib and 32 in placebo group. The mean age of the
patients was 30 years and most of the injury came from
sports injury. There were no significant differences
among groups in all demographic characteristics. The
duration of injury, associated injuries, concomitant sur-
geries, mean operative and tourniquet time, and mean
drain output were also no differences among groups
(Table 1). There were no differences among groups for
the time to first dose of analgesic medication, amount of
paracetamol and fentanyl used, and patient satisfaction
with pain control (Table 2). Although there were signifi-
cantly higher reports of constipation and fever in placebo
group, there was no significant difference in the numbers
of adverse event among the three groups (Table 3). The
etoricoxib group had significantly less pain intensity than
the other two groups at recovery room and up to 8 hours
period but no significance difference in all other evalua-
tion point, while celecoxib showed no significantly differ-
ence from placebo at any time point (Figure 1).
Discussion
Postoperative pain following arthroscopic ACL recon-
struction could be perceived by the patients immediately
in the recovery room as they were recovering from spinal
anesthesia, rose to peak intensities around 8 hours and
slowly decreased to acceptable level below 40 after
36 hours postoperatively. We found that only etoricoxib,
not celecoxib, was effective for use as preemptive analge-
sia in patients undergoing arthroscopic ACL reconstruc-
tion. However, the time to first dose of analgesic
medication, total amount of analgesics used, and patient’s
satisfaction with pain control were also not significantly
different among the three groups.
Preemptive analgesia is a new strategy of postoperative
pain management. The key concept is to prevent the
altered sensory processing from surgical process. There
are a number of medications being tested for this
Table 1 Patient characteristics among groups
Characteristics Etoricoxib Celecoxib Placebo P-value
· Number 35 35 32
· Sex: Male (%) 33 (94.29) 31 (88.57) 28 (87.50) 0.375
· Mean duration of injury (SD) 18.22 (15.93) 28.31 (44.87) 35.41 (49.23) 0.477
· Associated injury 0.234
None 9 (25.71) 7 (20.00) 9 (28.13)
Medial meniscus 16 (45.71) 17 (48.57) 10 (31.25)
Lateral meniscus 5 (14.30) 7 (20.00) 6 (18.75)
Both meniscus 2 (5.71) 1 (2.86) 7 (21.88)
Articular injury 2 (5.71) 2 (5.71) 0 (0)
Both meniscus and articular injury 1 (2.86) 1 (2.86) 0 (0)
· Concomitant surgery 0.75
None 13 (37.15) 13 (37.14) 13 (40.63)
Medial menisectomy 13 (37.15) 11 (31.43) 10 (31.25)
Lateral menisectomy 3 (5.87) 5 (14.29) 6 (18.75)
Both medial and lateral menisectomy 2 (5.71) 0 (0) 2 (6.06)
Cartilage debridement 2 (5.71) 5 (14.29) 2 (6.25)
· Mean pain score before surgery (SD) 11.17 (17.76) 14.0 (21.58) 15.62 (26.39) 0.721
· Mean operative time (SD) 52.50 (10.76) 60.73 (14.20) 60.45 (20.30) 0.223
· Mean tourniquet time (SD) 56.08 (9.69) 63.25 (12.84) 63.90 (19.33) 0.089
· Mean drain output at 24 hr./ml (SD) 170.77 (183.68) 218.94(231.48) 143.28(106.40) 0.663
Table 2 Medication usages and patient satisfaction among groups
Variables Etoricoxib Celecoxib Placebo P-value
· Mean number of rescue medication (SD)
- Paracetamol (Tabs.500 mg.) 3.05 (2.44) 3.50 (2.83) 4.65 (3.49) 0.648
- Amount of fentanyl use (micrograms) 114.64 (89.99) 112.8 (84.43) 171.43 (129.56) 0.222
· Time to first dose of fentanyl (hr) 5.89 (5.67) 5.83 (10.22) 5 (5.85) 0.55
· Mean pain satisfaction score 78.14 (14.04) 80.68 (16.86) 72.22 (18.36) 0.167
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strategy, including opioids, anesthetic drugs and NSAIDs
with conflicting results [3-5,7,21,22]. Although there
have been some studies evaluating the efficacy of
NSAIDs for preemptive analgesia, our study is the first
head-to-head study of using COX-2 inhibitor NSAIDs
for preemptive analgesia for major orthopaedic surgery.
Our results found that only etoricoxib was efficacious
for use as preemptive analgesia after major orthopaedic
surgery. Efficacy of etoricoxib over celecoxib and the
placebo may explained by the better or stronger analge-
sic efficacy of this drug. Other study had also demon-
strated the efficacy of etoricoxib for perioperative pain
control. Rasmussen et al use etoricoxib 120 mg/day
from day 1 to day 7 postoperatively in the patient
undergoing arthroplasty [17]. They found that etoricoxib
provided analgesia that was similar to controlled-release
naproxen sodium on day 1 and superior to placebo with
reduced supplement opioid used over 7 days [17].
The only head-to-head comparison between etoricoxib
and celecoxib was in study of Bingham III, et al. [23]
who compared the efficacy of etoricoxib 30 mg with the
generally maximum recommended dose of celecoxib,
200 mg, in the treatment of osteoarthritis (OA) in two
identically designed studies. They concluded that etori-
coxib 30 mg per day was at least as effective as cele-
coxib 200 mg per day and had similar safety in the
treatment of knee and hip OA; both were superior to
placebo [23]. Our study reached a contrast conclusion
that only etoricoxib, not celecoxib, is effective for redu-
cing pain intensity at the recovery room up to 8 hours
postoperatively.
Conclusions
Etoricoxib is more effective than celecoxib and placebo
for using as preemptive analgesia for acute postoperative
pain control in patients underwent arthroscopic anterior
cruciate ligament reconstruction.
Table 3 Adverse events among groups
Adverse events Etoricoxib Celecoxib Placebo P-value
· Gastrointestinal
Dyspepsia 1 (2.85) 0 (0) 2 (6.25) 0.436
Flatulence 0 (0) 0 (0) 1 (3.13) 0.205
Nausea 1 (2.85) 0 (0) 0 (0) 0.233
Vomiting 0 (0) 0 (0) 2 (6.25) 0.07
Constipation 0 (0) 0 (0) 3 (9.38) 0.025*
· Neurological
Dizziness 3 (8.57) 2 (5.71) 4 (12.50) 0.59
Headache 0 (0) 1 (2.85) 2 (6.25) 0.133
· Cardiovascular
Tachycardia 2 (5.71) 0 (0) 3 (9.38) 0.52
Hypertension 3 (8.57) 2 (5.71) 5 (15.63) 0.35
· Renal
Oliguria 0 (0) 0 (0) 1 (3.13) 0.205
· Other
Fever 2 (5.71) 12(34.29) 11 (34.38) 0.005*
* Statistically significant among groups.
Figure 1 Pain Intensity among each group during 48 hour after surgery.
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